MMWR Morb Mortal Wkly Rep. 2015 Feb 27;64(7):193.
The Food and Drug Administration (FDA) has cleared the Xpert MTB/RIF Assay (Cepheid; Sunnyvale, California) with an expanded intended use that includes testing of either one or two sputum specimens as an alternative to examination of serial acid-fast stained sputum smears to aid in the decision of whether continued airborne infection isolation (AII) is warranted for patients with suspected pulmonary tuberculosis. This change reflects the outcome of a recent multicenter international study demonstrating that negative Xpert MTB/RIF Assay results from either one or two sputum specimens are highly predictive of the results of two or three negative acid-fast sputum smears.
美国食品药品监督管理局(FDA)已批准Xpert MTB/RIF检测(塞菲德公司;加利福尼亚州桑尼维尔)扩大预期用途,包括检测一份或两份痰标本,作为连续抗酸染色痰涂片检查的替代方法,以帮助决定对疑似肺结核患者是否有必要继续进行空气传播感染隔离(AII)。这一变化反映了最近一项多中心国际研究的结果,该研究表明,一份或两份痰标本的Xpert MTB/RIF检测结果为阴性,高度预示着两份或三份抗酸痰涂片结果为阴性。